Skip to contentX
Xenetic Biosciences, Inc.
X
XBIOXenetic Biosciences, Inc. Q2 2023 · 10-Q
Revenue$651.01K$651.01K+56.2% vs Q2 2022 Net Income-$1.05M-$1.05MN/M vs Q2 2022 EPS Diluted-$0.69-$0.69N/M vs Q2 2022 Operating Income-$1,198,188N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenetic Biosciences, Inc. · CIK 1534525 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-184.1%+460.8 pt vs Q2 2022
Net margin-161.4%+479.8 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 10, 2023 · 41 d after period end